Category
"We are creating a new causal AI category."
Mutates
"Customer pull matters more than category originality at this stage."
Vision discounted
CLARITYINVEST
Two real diagnostics, anonymized
We predicted what the room would say before the room said it. Here's the receipt.
Every ClarityInvest diagnostic is produced blind — before we've seen any feedback from the founder's real investor conversations. What follows are two anonymized cases, shown exactly as delivered, next to what the room actually said afterward.
3–4 / 5
Objections and kill signals independently confirmed by the room, typical across engagements
1–2 / 5
Missed or reprioritized once real feedback came in — tracked, not hidden
We're not claiming a guaranteed close rate — that's a different, harder claim, and one we're not going to fabricate. This is a claim about prediction accuracy, and it's the one we can actually show our work on.
Case 01 · Named-fund sprint
"Interesting AI company with early revenue — but the whole decision turns on whether the platform channel is real enough to produce low-CAC growth."
Anonymized
Seed, $2M ask
AI / data infrastructure
Specific fund, named partners
The founder was three weeks from a call with a specialist fund's two decision-makers. Before that call happened, and before we'd heard a word of real feedback, we delivered the sentence above as our prediction of what the fund would carry into its investment committee — plus the six specific things most likely to stop the deal.
Compression map — what survives, mutates, or dies in the room
This is the mechanic, shown on five of the seventeen claims we mapped for this founder.
| Dimension | Founder's claim | Room's version |
|---|---|---|
| Category | "We are creating a new causal AI category." Mutates |
"Customer pull matters more than category originality at this stage." Vision discounted |
| Distribution | "We have integrations with major platforms." Mutates |
"Integration is not distribution unless it creates customer access, usage, and revenue." Becomes the hinge |
| Revenue | "We have early booked revenue and a late-stage pipeline." Survives |
"Good start, but the conversion path must be shown bottom-up." Evidence discounted forward |
| Use of funds | "The round converts pipeline and scales revenue across platforms." Mutates |
"The target is clear. The mechanics need proof before the room can underwrite it." Turns into diligence pressure |
| Team | "10+ years of domain and product experience." Survives |
"Enough credibility for a Seed look." Holds |
Distribution
"We have integrations with major platforms."
Mutates
"Integration is not distribution unless it creates customer access, usage, and revenue."
Becomes the hinge
Revenue
"We have early booked revenue and a late-stage pipeline."
Survives
"Good start, but the conversion path must be shown bottom-up."
Evidence discounted forward
Six kill signals, delivered before the call
What was most likely to stop this deal.
01
"No CAC" without contractual proof
Integration ≠ commercial distribution. The room would ask for revenue and customer access per platform, not just API access.
02
Revenue bridge without a bottoms-up model
The 18-month ARR target needed outlets, attach rate, ACV, and sales capacity shown explicitly — not asserted.
03
Cap table friction
A broad shareholder base and a note overhang needed a clean pro forma before the fund could lead comfortably.
What happened next: on the walkthrough call after the founder's real conversations, four of the six flagged signals were confirmed near word-for-word — including the exact "integration is not distribution" objection. One was reprioritized (the cap table mattered less than predicted); one hadn't surfaced yet at that stage of diligence.
Case 02 · Capital lane diagnostic
"Credible team and strong channel access — but the immediate question isn't which investor to pitch. It's which capital should fund the next proof state."
Anonymized
Pre-seed, zero runway
Health / diagnostics platform
Multi-lane capital sequencing
This founder had been treating their raise as one €1.5m ask and getting rejected by generalist VCs. The diagnostic identified something different: the company actually had three separate financing needs — a small non-dilutive validation grant, a proof bridge, and the full seed — and was taking all three to the wrong market at once.
Correcting the founder's own read
The founder believed venture was "blocked." The evidence said otherwise.
What the founder believed
A pattern of VC rejections meant venture capital was closed to this company at this stage — the founder attributed it to category crowding and network gaps.
What the evidence showed
One fund had actually progressed the company through multiple diligence calls before choosing a different deal — a signal of real, if conditional, venture interest, not a closed door.
The corrected verdict: venture moved from "blocked" to "conditional" — worth keeping alive selectively, but not the founders' best use of time with zero runway. The priority became sequencing non-dilutive and strategic capital first, to buy the runway and real-world proof that would make the next venture conversation stronger.
What changed next
A €1.5m ask became three separate, sequenced moves.
The founders split effort three ways: a fast non-dilutive grant, a proof-bridge raise from strategic and angel sources, and the full seed held until real-world validation existed. Founder time — the scarcest resource at zero runway — went to the two moves most likely to close.
Your pipeline probably has a version of one of these two leaks.
The intake takes two minutes and tells you honestly which one — or if ClarityInvest isn't the right tool for where you are.
No commitment · Free routing call · Diagnostics from €2,500